XORTX Therapeutics Inc.
corporate_fare Company Profile
XORTX Therapeutics Inc. (NASDAQ:XRTX) is a publicly traded company in the Life Sciences sector. Wiseek monitors XRTX SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- XORTX Reports $2.5M Loss, Going Concern Warning, and Material Weakness
- XORTX Appoints Co-CEO, Details Path to NDA for Gout Drug XRx-026
- XORTX to Delist from TSX Venture Exchange, Focus on NASDAQ Listing
- XORTX Therapeutics Closes Highly Dilutive $5M Public Offering at Deep Discount
- XORTX Completes $5M Public Offering, Significantly Diluting Shareholders at Discounted Price
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for XRTX, detected from its recent SEC filings · based on capital-structure filings through 2026-05-19.
Public Offering Finalized · Significant Dilution
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
XRTX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.